Mind Relief Foundation’s Post

Just before the new year, the FDA made a huge breakthrough in how we might treat opioid misuse for decades to come. The Administration has just approved the first-ever medical device designed to identify elevated risk factors for developing opioid use disorder.    This groundbreaking approval opens new doors in the fight against substance misuse. The AvertD test uses a swab for consenting patients who have no prior use of orally administered opioids to test for genetic information that could point to risks of OUD. This is a huge step forward in intervention and personalized care and a game-changer in our efforts to combat the opioid crisis, especially among the youth. By addressing these risk factors early on, we're taking a proactive step in the broader conversation around substance misuse. Given the available evidence and the urgent need for medical devices that can make a positive impact on the overdose crisis, the FDA determined that there is a reasonable assurance of AvertD's safety and effectiveness. Here’s to hoping that further innovation in the field of science can lead to similar, safe breakthroughs for managing the substance misuse crisis in the years to come. Check out the press release in the comments below.  #FDAApproval #OpioidCrisis #SubstanceMisuse #HealthcareInnovation

Review an interactive resource summarizing data from an ongoing Phase 3 clinical study evaluating the long-term efficacy and safety profile of an oral therapy for the treatment of patients with moderate-to-severe #AtopicDermatitis (AD). View the results of this planned interim analysis here: https://lnkd.in/eAWVupuJ

New findings about for GLP-1 agonists were published this week by researchers from Epic, an electronic health record company. Researchers found that people with diabetes who started taking most versions of GLP-1 agonists were between 11% and 65% less likely to be newly diagnosed with depression than people with diabetes who didn’t take one of the drugs. Similar reductions were observed for patients without diabetes taking the GLP-1s as well! Read the full article here: https://lnkd.in/eNBmd--E 🖥 AyaFusion.com #downersgrove #downersgroveweightloss #semaglutidewesternsuburbs #semaglutideweightloss #semaglutidechicago #lombard #lombardweightloss #tirzepatide #tirzepatideweightloss #tirzepatidechicago

Peter C. Gøtzsche, Professor in Clinical Research Design & Analysis, and a Specialist in Internal Medicine‼️ "2 years ago I found out that our prescription drugs are the third leading cause of death after heart disease and cancer‼️ Our drugs kill around two hundred thousand people in America every year. And half of those people die while they do what their doctors told them. So they die because of the side effects, the other half die because of errors and it's often the doctors that make errors,because any drug may come with twenty, thirty or forty warnings, contraindications and precautions and so on. No doctor in the world knows about all this‼️ So they give patients drugs they should not have given that interact dangerously with other drugs or food items then the patients die"‼️🙏👇 YouTube 🎥👇👇 https://lnkd.in/ezbpRuzu Gøtzsche's📚'Deadly Medicine & Organised crime: How Big Pharma Corrupted Healthcare' was published in 2013‼️

🗑 WEEKLY WAR ON WASTE (WWW); We need 'de-prescribing' to reduce the spend on drugs that do more harm than good, about 10% is the estimate by the DHSC, but we need to do much more just stopping drugs. As this letter says this is too depressing - https://lnkd.in/eXGkT3wg What we need is 'Re-prescribing' of high value drug therapy and of non-drug therapy, which is what we are doing in a number of populations. Lets do it

How can we change the standard of care? How does neurostimulation become an earlier treatment option for chronic pain? It is an ambitious idea to think a DEVICE could replace repeat drug injections to manage chronic pain. For that to be a reality, the device would have to be fast and easy like a drug, "invisible" like a drug, and needs to be cost effective for providers, patients, and insurers. These are all foundational ideas for how we are developing the Injectrode. Featured here are images from our first-in-human study: A) Fluoroscopic AP view showing bilateral Injectrode placement in the lower back. B) Placement site on day 25, demonstrating virtually invisible placement site after healing. This is what we mean when we say “invisible like a drug.” Patient privacy is important. Note: Investigational device | Limited by federal (United States) law to investigational use only #Injectrode #PainManagement #ChronicPain #PNS #Neuromodulation

A gut wrenching article from El Pais. It references a study published 7 August 2023 in JAMA, Journal of the American Medical Association that reported only one in five people with #opioidusedisorder receive the medications considered the gold standard for opioid treatment, such as #methadone, #buprenorphine or extended-release #naltrexone. #medicationassistedtreatment #opioidcrisis #opioidepidemic Verinetics https://lnkd.in/enu4qAcc

The blog post, Unseen Perils: The Silent Epidemic of Prescription Drug Misuse and Its Alarming Societal Impact explores the widespread issue of prescription drug misuse, highlighting the danger hidden within our own homes. It underscores the need for a multipronged approach including education, regulation, and monitoring, and emphasizes on shifting societal understanding of addiction as a treatable medical condition rather than a moral failing. The blog advocates for comprehensive strategies centered on prevention, treatment, and policy intervention to confront and mitigate this alarming societal problem.

Daily Critical Care Pearls #58: Digoxin Toxicity - Part 1 📌 The drug has a narrow therapeutic window, but there is not always correlation between the digoxin level and toxicity 📌 Some patients may have a level in the toxic range and be asymptomatic and some may be in the therapeutic range but experience toxicity 📌 A level collected before 4 hours has elapsed from ingestion may not represent an accurate level and could be falsely elevated - 4 to 6 hours post ingestion allows for distribution and a more accurate level 📌 Common rhythms seen in digoxin toxicity are: Premature ventricular contractions, Bradycardia, Atrial tacharrhtymia with AV block, Ventricular bigeminy Junctional rhythm, AV block, Ventricular tachycardia, Ventricular fibrillation 📌 Acute toxicity may involve the patient being assymptomatic after ingestion for a few hours followed by severe GI symptoms such as nausea, vomiting, abdominal pain, and anorexia 📌 Visual disturbances are also characteristic of toxicity but the classic finding of xanthopsia where everything appears yellow is often missing 📌 Hyperkalemia in acute toxicity is both a marker of toxicity and a predictor of mortality #criricalcare #pharmacy #medicine #clinicalpharmacy #pearls

The blog post, Unseen Perils: The Silent Epidemic of Prescription Drug Misuse and Its Alarming Societal Impact explores the widespread issue of prescription drug misuse, highlighting the danger hidden within our own homes. It underscores the need for a multipronged approach including education, regulation, and monitoring, and emphasizes on shifting societal understanding of addiction as a treatable medical condition rather than a moral failing. The blog advocates for comprehensive strategies centered on prevention, treatment, and policy intervention to confront and mitigate this alarming societal problem.